Amid Covid vaccine success, BioNTech plans to return €2bn to shareholders 0 30.03.2022 19:47 Economictimes.indiatimes.com After the success of the covid vaccine, BioNTech is planning to return €2bn to shareholders. BioNTech will continue the clinical trial to boost protection against the Omicron variant. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
